	US 12,478,639 B2
	Ocular lubricant formulations
William Stringer, Portland, OR (US); Michael Hanrahan, Portland, OR (US); and Patrick H. Witham, Portland, OR (US)
Assigned to HARROW IP, LLC, Nashville, TN (US)
Filed by Harrow IP, LLC, Nashville, TN (US)
Filed on Mar. 4, 2024, as Appl. No. 18/594,231.
Application 18/594,231 is a continuation of application No. 17/268,256, granted, now 11,918,603, previously published as PCT/US2019/048360, filed on Aug. 27, 2019.
Claims priority of provisional application 62/725,152, filed on Aug. 30, 2018.
Prior Publication US 2024/0197773 A1, Jun. 20, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/79 (2006.01); A61F 9/00 (2006.01); A61K 31/765 (2006.01); A61K 47/02 (2006.01); A61K 47/10 (2017.01); A61K 47/18 (2017.01); A61K 47/24 (2006.01); A61K 47/26 (2006.01)

CPC A61K 31/79 (2013.01) [A61F 9/0008 (2013.01); A61K 31/765 (2013.01); A61K 47/02 (2013.01); A61K 47/10 (2013.01); A61K 47/183 (2013.01); A61K 47/24 (2013.01); A61K 47/26 (2013.01)]

7 Claims

1. A method of treating dry eye, the method comprising administering to a subject in need thereof a composition consisting of:

(a) povidone;

(b) fully hydrolyzed polyvinyl alcohol;

(d) sodium chloride;

(e) boric acid;

(f) disodium edetate dihydrate;

(g) potassium chloride;

(h) glycerin;

(i) ethyl alcohol;

(j) lecithin;

(k) polysorbate 80;

(l) a pH adjusting agent; and

(m) water;

wherein

the fully hydrolyzed polyvinyl alcohol has a molecular weight in a range of 20,000 to 200,000 daltons;

the composition is an ophthalmic composition; and

the composition is preservative free.